| scholarly article | Q13442814 |
| P50 | author | Alexandra Gruss | Q37842263 |
| Christine Pourcel | Q56458925 | ||
| Claire Morvan | Q57093871 | ||
| David Halpern | Q57093883 | ||
| Karine Gloux | Q57093893 | ||
| P2093 | author name string | Charles Soler | |
| Gilles Lamberet | |||
| Hoang Vu Thien | |||
| Mélanie Guillemet | |||
| P2860 | cites work | Nasal microenvironments and interspecific interactions influence nasal microbiota complexity and S. aureus carriage | Q24614067 |
| New design platform for malonyl-CoA-acyl carrier protein transacylase | Q27660001 | ||
| Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme–Product Complex | Q27678258 | ||
| Staphylococcus aureus FabI: Inhibition, Substrate Recognition, and Potential Implications for In Vivo Essentiality | Q27679034 | ||
| Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor | Q27683440 | ||
| Triclosan promotes Staphylococcus aureus nasal colonization | Q28384355 | ||
| Triclosan: a widely used biocide and its link to antibiotics | Q29391509 | ||
| A tale of two functions: enzymatic activity and translational repression by carboxyltransferase | Q33700075 | ||
| Waves of resistance: Staphylococcus aureus in the antibiotic era. | Q33854398 | ||
| Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus | Q34142386 | ||
| Emergence of a novel subpopulation of CC398 Staphylococcus aureus infecting animals is a serious hazard for humans | Q34637716 | ||
| Staphylococcus epidermidis isolated in 1965 are more susceptible to triclosan than current isolates | Q34685701 | ||
| Staphylococcus aureus but not Listeria monocytogenes adapt to triclosan and adaptation correlates with increased fabI expression and agr deficiency | Q34880970 | ||
| The impact of triclosan on the spread of antibiotic resistance in the environment | Q34969983 | ||
| Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. | Q35216999 | ||
| The MUT056399 inhibitor of FabI is a new antistaphylococcal compound | Q35270339 | ||
| Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? | Q35350186 | ||
| Corynebacterium accolens Releases Antipneumococcal Free Fatty Acids from Human Nostril and Skin Surface Triacylglycerols. | Q35886154 | ||
| Evaluation of molecular typing methods in characterizing a European collection of epidemic methicillin-resistant Staphylococcus aureus strains: the HARMONY collection | Q35913887 | ||
| Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from Staphylococcus aureus. | Q36276367 | ||
| Fatty acids in bovine milk fat. | Q37000831 | ||
| Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake | Q37147269 | ||
| Staphylococcus aureus fatty acid auxotrophs do not proliferate in mice | Q37263376 | ||
| Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials | Q37329885 | ||
| Triclosan: environmental exposure, toxicity and mechanisms of action | Q37861068 | ||
| Biocide tolerance in bacteria | Q38076006 | ||
| Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains | Q39565510 | ||
| Growth requirements of some small-colony-forming variants of Staphylococcus aureus | Q40235354 | ||
| Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin | Q40758601 | ||
| Dissemination of Novel Antimicrobial Resistance Mechanisms through the Insertion Sequence Mediated Spread of Metabolic Genes | Q42137262 | ||
| In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics | Q43026765 | ||
| Essentiality of FASII pathway for Staphylococcus aureus | Q43187921 | ||
| A novel resistance mechanism to triclosan that suggests horizontal gene transfer and demonstrates a potential selective pressure for reduced biocide susceptibility in clinical strains of Staphylococcus aureus | Q44219816 | ||
| Serum fatty acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: the Kumihama study | Q44307887 | ||
| Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA). | Q44608394 | ||
| First isolation of oleate-dependent Enterococcus faecalis small-colony variants from the umbilical exudate of a paediatric patient with omphalitis | Q46989674 | ||
| Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens | Q57244151 | ||
| Reduced Enterobacterial and Increased Staphylococcal Colonization of the Infantile Bowel: An Effect of Hygienic Lifestyle? | Q58848624 | ||
| The Group B Streptococcus NADH oxidase Nox-2 is involved in fatty acid biosynthesis during aerobic growth and contributes to virulence | Q59809276 | ||
| The fatty acid profile of the skin surface lipid layer in papulopustular rosacea | Q63248590 | ||
| Lipid composition of sputum from patients with asthma and patients with cystic fibrosis | Q67027021 | ||
| The saturated methyl branched fatty acids of adult human skin surface lipid | Q67051489 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fatty acid | Q61476 |
| Staphylococcus aureus | Q188121 | ||
| P577 | publication date | 2017-02-13 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus | |
| P478 | volume | 61 |
Search more.